Clinical Trials Logo
  1. Home
  2. Essential Hypertension
  3. NCT00608153
  4. Details
NCT00608153 Clinical Trial

Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

Essential Hypertension Clinical Trial

— CoCa  

Official title:
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00608153
Other study ID # NIS-CGE-ATA-2007/1
Secondary ID
Status Completed
Phase N/A
First received January 23, 2008
Last updated February 5, 2008
Start date January 2007
Est. completion date September 2007

Study information
Verified date January 2008
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Observational

Clinical Trial Summary

The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

Recruitment information / eligibility
Status Completed
Enrollment 1773
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- essential hypertension

- under candesartan treatment

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
AstraZeneca

Outcome
Type Measure Description Time frame Safety issue
Primary To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period. app. 3 monthly
Secondary To assess under naturalistic conditions the subject's reason(s) for being compliant or non-compliant with the intake of the pre-scribed dose of candesartan or candesartan/HCT app. 3 monthly
Secondary To assess under naturalistic conditions the subject's reason(s) for withdrawal of the pre-scribed dose of candesartan or candesartan/HCT app. 3 monthly
Secondary To assess under naturalistic conditions whether physicians are using procedures to improve the subject's compliance regarding the intake of candesartan or candesartan/HCT and to get insight in the type and effects of these procedures app. 3 monthly
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Recruiting NCT05526703 - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00139698 - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Phase 3
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Not yet recruiting NCT06041529 - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Phase 4
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function